Company Overview of Karolinska Institutet
Karolinska Institutet is a Swedish university, which specializes in medicine. Several companies in the field of medicine and biotechnology have been founded as a result of the university's research programmes. As a result, Karolinska Institutet cooperates closely with the private sector and has created an investment arm (Karolinska Investment Fund) in order to enhance its scientists' innovations. Founded in 1810, the company is headquartered in Stockholm.
Founded in 1810
46 8 728 64 00
46 8 31 11 01
Key Executives for Karolinska Institutet
Professor of Environmental Toxicology
Professor of Pharmacology
Professor of Neurobiology
Compensation as of Fiscal Year 2014.
Karolinska Institutet Key Developments
Karolinska Institutet Presents at Swedish-American Life Science Summit 2014, Aug-21-2014 02:00 PM
Aug 21 14
Karolinska Institutet Presents at Swedish-American Life Science Summit 2014, Aug-21-2014 02:00 PM. Venue: EY Headquarters, Stockholm, Sweden. Speakers: Anders Hamsten, President.
Karolinska Institutet Presents at Swedish American Life Science Summit 2013, Aug-22-2013
Aug 22 13
Karolinska Institutet Presents at Swedish American Life Science Summit 2013, Aug-22-2013. Venue: Box 639, SE-114 11 Stockholm, Sweden. Presentation Date & Speakers: Aug-22-2013, Anders Hamsten, President, Bengt Winblad, Professor of Geriatrics, Kenneth R Chien, Professor of Cardiovascular Research. Aug-23-2013, Johanna Adami, Professor.
AstraZeneca PLC and Karolinska Institutet Intend to Create an Integrated Translational Research Centre
Mar 21 13
AstraZeneca PLC and Karolinska Institutet announced their intention to create an Integrated Translational Research Centre for cardiovascular and metabolic disease and regenerative medicine located at Karolinska Institutet's site in Stockholm, Sweden. The centre will be set up to conduct preclinical and clinical studies aimed at advancing the understanding of cardiovascular and metabolic disease pathophysiology and assessing new drug targets for AstraZeneca's two biotech units, AstraZeneca Innovative Medicines and Early Development (iMed) and MedImmune. Building on the organisations' longstanding collaboration, the Centre will initially run for a period of five years and will be made up of between 20 and 30 scientists, including a number of AstraZeneca scientists. In addition, AstraZeneca will contribute up to $20 million per annum, and Karolinska Institutet will contribute expertise and facilities. The Centre is expected to be operational by mid-2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|